382 related articles for article (PubMed ID: 32174772)
1. Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC).
Le K; Wang J; Zhang T; Guo Y; Chang H; Wang S; Zhu B
Int J Med Sci; 2020; 17(4):422-427. PubMed ID: 32174772
[No Abstract] [Full Text] [Related]
2. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
3. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
4. From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma.
Montemagno C; Cassim S; Pouyssegur J; Broisat A; Pagès G
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517181
[TBL] [Abstract][Full Text] [Related]
5. Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer.
Kendrick ZW; Firpo MA; Repko RC; Scaife CL; Adler DG; Boucher KM; Mulvihill SJ
HPB (Oxford); 2014 Jul; 16(7):670-6. PubMed ID: 24308545
[TBL] [Abstract][Full Text] [Related]
6. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.
Yao H; Yang Z; Liu Z; Miao X; Yang L; Li D; Zou Q; Yuan Y
Cancer Biomark; 2016; 17(4):397-404. PubMed ID: 27689616
[TBL] [Abstract][Full Text] [Related]
7. [Expression and clinical significance of Tspan 1 and Integrin α6 in human pancreatic ductal adenocarcinoma].
Shi G; Dong M; Sheng W; Zhou J; Yu D; Sun W
Zhonghua Wai Ke Za Zhi; 2014 Oct; 52(10):781-6. PubMed ID: 25573220
[TBL] [Abstract][Full Text] [Related]
8. HBXIP protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Zhou X; Wang X; Duan J; Sun W; Chen Z; Li Q; Ou Z; Jiang G; Ren X; Liu S
Pathol Res Pract; 2019 Feb; 215(2):343-346. PubMed ID: 30583814
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.
Zhang K; Yao H; Yang Z; Li D; Yang L; Zou Q; Yuan Y; Miao X
Clin Transl Oncol; 2016 Apr; 18(4):352-9. PubMed ID: 26887611
[TBL] [Abstract][Full Text] [Related]
10. Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness.
Weidemann S; Perez D; Izbicki JR; Neipp M; Mofid H; Daniels T; Nahrstedt U; Jacobsen F; Bernreuther C; Simon R; Steurer S; Burandt E; Marx AH; Krech T; Clauditz TS; Jansen K
Cancer Invest; 2021 Oct; 39(9):711-720. PubMed ID: 34143695
[TBL] [Abstract][Full Text] [Related]
11. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
12. The Clinical and Pathological Significance of Nectin-2 and DDX3 Expression in Pancreatic Ductal Adenocarcinomas.
Liang S; Yang Z; Li D; Miao X; Yang L; Zou Q; Yuan Y
Dis Markers; 2015; 2015():379568. PubMed ID: 26294807
[TBL] [Abstract][Full Text] [Related]
13. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
Wehrli M; Guinn S; Birocchi F; Kuo A; Sun Y; Larson RC; Almazan AJ; Scarfò I; Bouffard AA; Bailey SR; Anekal PV; Montero Llopis P; Nieman LT; Song Y; Xu KH; Berger TR; Kann MC; Leick MB; Silva H; Salas-Benito D; Kienka T; Grauwet K; Armstrong TD; Zhang R; Zhu Q; Fu J; Schmidts A; Korell F; Jan M; Choi BD; Liss AS; Boland GM; Ting DT; Burkhart RA; Jenkins RW; Zheng L; Jaffee EM; Zimmerman JW; Maus MV
Clin Cancer Res; 2024 May; 30(9):1859-1877. PubMed ID: 38393682
[TBL] [Abstract][Full Text] [Related]
14. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
[TBL] [Abstract][Full Text] [Related]
15. RACK1 overexpression associates with pancreatic ductal adenocarcinoma growth and poor prognosis.
Li X; Xiao Y; Fan S; Xiao M; Wang X; Chen X; Li C; Zong G; Zhou G; Wan C
Exp Mol Pathol; 2016 Oct; 101(2):176-186. PubMed ID: 27498047
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic metastases of renal clear cell carcinoma: a clinicopathological study of 11 cases with special emphasis on the usefulness of PAX2 and mesothelin for the distinction from primary ductal adenocarcinoma of the pancreas.
Gnemmi V; Leroy X; Triboulet JP; Pruvot FR; Villers A; Leteurtre E; Buob D
Anal Quant Cytopathol Histpathol; 2013 Jun; 35(3):157-62. PubMed ID: 24344503
[TBL] [Abstract][Full Text] [Related]
17. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation.
Chen SH; Hung WC; Wang P; Paul C; Konstantopoulos K
Sci Rep; 2013; 3():1870. PubMed ID: 23694968
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathological significance of the expression of carbonic anhydrase I and II in human pancreatic cancer].
Sheng WW; Dong M; Zhou JP; Kong FM; Li YJ
Zhonghua Yi Xue Za Zhi; 2012 Dec; 92(48):3407-11. PubMed ID: 23327700
[TBL] [Abstract][Full Text] [Related]
19. A tumorigenic factor interactome connected through tumor suppressor microRNA-198 in human pancreatic cancer.
Marin-Muller C; Li D; Bharadwaj U; Li M; Chen C; Hodges SE; Fisher WE; Mo Q; Hung MC; Yao Q
Clin Cancer Res; 2013 Nov; 19(21):5901-13. PubMed ID: 23989979
[TBL] [Abstract][Full Text] [Related]
20. Identification of ANXA1 as a lymphatic metastasis and poor prognostic factor in pancreatic ductal adenocarcinoma.
Liu QH; Shi ML; Bai J; Zheng JN
Asian Pac J Cancer Prev; 2015; 16(7):2719-24. PubMed ID: 25854353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
